Viracept to be discontinued

Patients currently undergoing treatment with Viracept (nelfinavir) will need to be switched to an alternative therapy before production of the protease inhibitor ends early next year.

Decreasing demand and exclusion from clinical guidelines has led to discontinuation of Viracept | SCIENCE PHOTO LIBRARY
Decreasing demand and exclusion from clinical guidelines has led to discontinuation of Viracept | SCIENCE PHOTO LIBRARY

According to manufacturer Roche, the decision to discontinue Viracept was based on several factors, including decreasing demand and exclusion of the drug from most clinical guidelines. In addition, alternative treatment options with improved risk-benefit profiles are now available.

Viracept is indicated in antiretroviral combination treatment of HIV infection in adults, adolescents and children aged three years and over.

Clinicians are advised not to start any new patients on Viracept and to discuss alternative treatment options with those patients currently receiving the drug.

View Viracept drug record

Further information: Roche

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...